Ovarian clear cell carcinoma is a distinct epithelial ovarian cancer subtype with unique molecular features and relative chemoresistance compared with high-grade serous carcinoma.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary on February 18, 2026. Braun brings over 20 years of healthcare experience and facilitated LIXTE's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07239622 |
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07002346 |
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma |
RECRUITING | PHASE3 |
| NCT06279104 |
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary |
RECRUITING | |
| NCT06065462 |
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 |
RECRUITING | PHASE1/PHASE2 |
| NCT05759312 |
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma |
UNKNOWN | PHASE1/PHASE2 |
| NCT05600998 |
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma |
UNKNOWN | NA |
| NCT05498597 |
AMT-151 in Patients With Selected Advanced Solid Tumours |
RECRUITING | PHASE1 |
| NCT05415098 |
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas |
UNKNOWN | PHASE1 |
| NCT05296512 |
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05281471 |
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
RECRUITING | PHASE3 |
